Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R; Cancer Med. 2019; 8(4):-1405.

Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination.

Rivera, FJ; de la Fuente, AG; Zhao, C; Silva, ME; Gonzalez, GA; Wodnar, R; Feichtner, M; Lange, S; Errea, O; Priglinger, E; OSullivan, A; Romanelli, P; Jadasz, JJ; Brachtl, G; Greil, R; Tempfer, H; Traweger, A; Bátiz, LF; Küry, P; Couillard-Despres, S; Franklin, RJM; Aigner, L; Glia. 2019; 67(8):1510-1525

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

Hammel, P; Berardi, R; Creemers, G; Van Cutsem, E; Cubillo, A; Greil, R; Wasan, H; Metges, J; Noel, M; Nygren, P; Osterlund, P; Seufferlein, T; Macarulla, T; Fountzilas, C; Gupta, A; Grummer, L; Kacel, S; Biswas-Baldwin, N; Kay, R; Youssoufian, H; El-Hariry, I; Hidalgo, M ANN ONCOL. 2020; 31: S115-S115.

A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

Lordick, F; Orra, EB; Cervantes, A; Dayyani, F; Rocha-Lima, C; Greil, R; van Laarhoven, H; Lorenzen, S; Kischel, R; Shitara, K; Chao, J ANN ONCOL. 2020; 31: S114-S114.

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Tran, B; Horvath, L; Dorff, TB; Greil, R; Machiels, JPH; Roncolato, F; Autio, KA; Rettig, M; Fizazi, K; Lolkema, MP; Fermin, AC; Salvati, M; Kouros-Mehr, H J CLIN ONCOL. 2020; 38(6):

TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Hammel, P; Berardi, R; Van Cutsem, E; Feliu, J; Greil, R; Wasan, HS; Metges, JP; Nygren, P; Osterlund, PJ; Noel, MS; Seufferlein, T; Creemers, GY; Gupta, A; Salesse, S; Biswas-Baldwin, N; Dion, H; Youssoufian, H; Garzon, FT; El-Hariry, I; Hidalgo, M J CLIN ONCOL. 2020; 38(4):

Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA)

Hecht, JR; Lonardi, S; Bendell, JC; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Lin, Y; Rao, S; Ryoo, BY J CLIN ONCOL. 2020; 38(4):

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran; Horvath, L; Rettig, M; Fizazi, K; Lolkema, MP; Dorff, TB; Greil, R; Machiels, JPH; Autio, KA; Rottey, S; Adra, N; Garje, R; Roncolato, F; Tagawa, ST; Shariat, SF; Salvati, M; Poon, S; Kouros-Mehr, H J CLIN ONCOL. 2020; 38(15):

Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score = 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Burtness, B; Rischin, D; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BG; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Ge, J; Swaby, R; Gumuscu, B; Harrington, K CANCER RES. 2020; 80(16):

Circulating tumor DNA-based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE-trial) AIO-KRK-0217

Folprecht, G; Reinacher-Schick, A; Tannapfel, A; Weitz, J; Kossler, T; Weiss, L; Aust, DE; von Bubnoff, N; Kramer, M; Thiede, C J CLIN ONCOL. 2020; 38(4):